Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD placebo-controlled study of NT-0167 in healthy volunteers
NL-OMON49667Phase 1Completed
- Sponsor
- NodThera
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory diseases and Neurodegenerative disorders (NDDs) comparing NT-0167 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and serious adverse events, Clinical laboratory tests and 18 more. Started Jan 2020; status: completed.
02
Drugs
NDM-101
03
Conditions
inflammatory diseasesNeurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on NL-OMON49667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49667.